24.06.2013 - British GlaxoSmithKline is participating in the new Kurma Biofund II in France. €17.5m of the €44m raised so far comes from GSK.
In a bid to identify promising new targets and drugs, British Pharma GlaxoSmithKline gains a foothold in a rare diseases venture fund. GSK said last week it will invest €17.5m in the Kurma Biofund II. It is the first venture capital fund dedicated to financing innovation in the rare diseases field through working with a network of European research institutes. Lead investor is the French firm Kurma Life Sciences Partners, with other backers including CDC Enterprises, Idinvest Partners and New Enterprise Associates. So far €44m has been raised. In April, GSK took a another bigger step when it decided to team up with Avalon Ventures in a deal worth up to €375m to fund ten drug discovery start-ups over the next three years (also see EuroBiotechNews Special May/2013).
Kurma Biofund I, valued at €51m, is still managed by Paris-based Kurma Life Sciences Partners. Like Biofund II this fund seeks the establishment of a new economic model for the financing of innovation – based on strategic partnerships with highly reputable biotechnology and medical research centers in France and the rest of Europe. Whereas Biofund II is targeted to rare diseases, Biofund I is largely concerned with life sciences and the health sector in general. Biofund I included enterprises ABM Medical, AM Pharma, Blink, Indigix, Key Neurosciences, Meiogenix, Pathoquest, Safe Orthopaedics, Umecrine and Zealand Pharma. Zealand recently made the news with its Sanofi-co-development. Since May Lyxumia has a European marketing authorisation as a diabetes therapy.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.